Drug
Taletrectinib clinical trials
Also written AB-106 and DS-6051b.
- studies test it
- 11
- open now
- 3
- in phase 3
- 2
- first study started
- 2014
Keep track of what changes. Save the taletrectinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Nuvation Bio Inc. (9) · Daiichi Sankyo Co., Ltd. (1) · Megan Kruse, MD (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses taletrectinib is read from its arms, and is right about nine times in ten.
Testing it · 11
- Study on the Effect of Famotidine on Pharmacokinetics of TaletrectinibNot yet recruitingPhase 1Nuvation Bio Inc.NCT07742384Written as Taletrectinib
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)RecruitingPhase 3Nuvation Bio Inc.NCT07154706Written as Taletrectinib
- A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsRecruitingPhase 3Nuvation Bio Inc.NCT06564324Written as Taletrectinib
- Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)SuspendedPhase 2Megan Kruse, MDNCT06214793Written as Taletrectinib
- A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneActive, not recruitingPhase 2Nuvation Bio Inc.NCT04395677Written as AB-106
- Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene FusionTerminatedPhase 2Nuvation Bio Inc.NCT04617054Written as AB-106
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCActive, not recruitingPhase 2Nuvation Bio Inc.NCT04919811Written as Taletrectinib
- A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051bCompletedPhase 1Nuvation Bio Inc.NCT02279433Written as DS6051b
- Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant TumorsCompletedPhase 1Daiichi Sankyo Co., Ltd.NCT02675491Written as DS-6051b
- A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PKCompletedPhase 1Nuvation Bio Inc.NCT05357820Written as AB-106, Itraconazole
- A Study on the Effect of AB-106 on the Pharmacokinetics of DigoxinCompletedPhase 1Nuvation Bio Inc.NCT05357911Written as AB-106, digoxin
Codes
What other systems call taletrectinib · ClinicalTrials.gg INT001753
- MeSH (NLM) C000720459taletrectinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) W4141180YDTALETRECTINIBConfirmed FDA, NLM
- NCI Thesaurus C118948TaletrectinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720459 | taletrectinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | W4141180YD | TALETRECTINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C118948 | Taletrectinib | One source FDA |
Also registered as taletrectinib adipate (UNII 6KLL51GNBG).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.